Suppr超能文献

新型冠状病毒肺炎(COVID-19):传染性和严重程度相关的危险因素。

COVID-19: Risk Factors Associated with Infectivity and Severity.

机构信息

Biomedical Sciences Program, University of Science and Technology, Zewail City of Science and Technology, Giza, Egypt.

Department of Microbial Genetics, AGERI, ARC, Giza, Egypt.

出版信息

Scand J Immunol. 2021 Jun;93(6):e13039. doi: 10.1111/sji.13039. Epub 2021 Mar 19.

Abstract

COVID-19 is highly transmissible; however, its severity varies from one individual to another. Variability among different isolates of the virus and among its receptor (ACE2) may contribute to this severity, but comorbidity plays a major role on disease prognosis. Many comorbidities have been reported to be associated with severe COVID-19 patients. We have collected data from retrospective studies which include clinical and epidemiological features of patients and categorize them into severe/mild, ICU/non-ICU and survivors/dead patients. In this review, we give an update about SARS-CoV-2 structure with emphasis on the possible reasons for the severity of the virus in patients. We also collected information and patients' data to highlight the relation between COVID-19 patients and comorbidities.

摘要

新型冠状病毒(COVID-19)具有高度传染性,但个体之间的严重程度存在差异。病毒的不同分离株及其受体(ACE2)的变异性可能导致这种严重程度的差异,但合并症在疾病预后中起着主要作用。已经报道了许多合并症与重症 COVID-19 患者相关。我们从回顾性研究中收集了数据,其中包括患者的临床和流行病学特征,并将其分为重症/轻症、重症监护病房(ICU)/非 ICU 和幸存者/死亡患者。在这篇综述中,我们介绍了 SARS-CoV-2 的结构,并重点介绍了病毒在患者中引起严重程度的可能原因。我们还收集了信息和患者数据,以强调 COVID-19 患者与合并症之间的关系。

相似文献

2
Coronavirus infection: An immunologists' perspective.冠状病毒感染:免疫学家的视角。
Scand J Immunol. 2021 Jun;93(6):e13043. doi: 10.1111/sji.13043. Epub 2021 Apr 7.
6
Immunological Biomarkers of COVID-19.新型冠状病毒肺炎的免疫学生物标志物。
Crit Rev Immunol. 2020;40(6):497-512. doi: 10.1615/CritRevImmunol.2020035652.
7
COVID-19 and Strategies for Its Therapeutics.COVID-19 与治疗策略。
Crit Rev Immunol. 2020;40(6):513-526. doi: 10.1615/CritRevImmunol.2020035633.
10
SARS-CoV-2-specific virulence factors in COVID-19.COVID-19 中的 SARS-CoV-2 特异性毒力因子。
J Med Virol. 2021 Mar;93(3):1343-1350. doi: 10.1002/jmv.26615. Epub 2020 Nov 1.

引用本文的文献

本文引用的文献

2
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验